Alto Neuroscience (NYSE:ANRO) Coverage Initiated by Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Alto Neuroscience (NYSE:ANROFree Report) in a research report released on Friday, Benzinga reports. The firm issued a buy rating and a $43.00 target price on the stock.

A number of other equities analysts have also recently weighed in on the company. William Blair reiterated an outperform rating on shares of Alto Neuroscience in a report on Wednesday, June 12th. Robert W. Baird assumed coverage on shares of Alto Neuroscience in a research note on Tuesday, February 27th. They set an outperform rating and a $32.00 target price for the company. Stifel Nicolaus reissued a buy rating and issued a $32.00 price target on shares of Alto Neuroscience in a research note on Monday, March 25th. Jefferies Financial Group assumed coverage on shares of Alto Neuroscience in a report on Tuesday, February 27th. They issued a buy rating and a $33.00 price objective on the stock. Finally, TD Cowen assumed coverage on shares of Alto Neuroscience in a report on Tuesday, February 27th. They issued an outperform rating for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of Buy and a consensus target price of $35.00.

Read Our Latest Report on Alto Neuroscience

Alto Neuroscience Trading Down 0.5 %

NYSE:ANRO opened at $11.00 on Friday. The company has a 50-day moving average price of $12.99. The company has a current ratio of 26.02, a quick ratio of 26.02 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 1-year low of $10.69 and a 1-year high of $24.00.

Alto Neuroscience (NYSE:ANROGet Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.30). Equities research analysts predict that Alto Neuroscience will post -2.93 EPS for the current year.

Insiders Place Their Bets

In other Alto Neuroscience news, CFO Nicholas Conrad Smith purchased 6,150 shares of Alto Neuroscience stock in a transaction dated Thursday, March 28th. The shares were acquired at an average price of $16.36 per share, with a total value of $100,614.00. Following the completion of the transaction, the chief financial officer now owns 26,866 shares of the company’s stock, valued at $439,527.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors have recently modified their holdings of the business. RA Capital Management L.P. acquired a new stake in shares of Alto Neuroscience in the first quarter valued at $21,267,000. Artal Group S.A. acquired a new stake in Alto Neuroscience in the 1st quarter valued at about $5,372,000. Zimmer Partners LP purchased a new position in shares of Alto Neuroscience in the 1st quarter valued at about $1,151,000. AWM Investment Company Inc. acquired a new position in shares of Alto Neuroscience during the first quarter worth about $4,592,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Alto Neuroscience during the first quarter worth approximately $9,788,000.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

See Also

Analyst Recommendations for Alto Neuroscience (NYSE:ANRO)

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.